Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA

BACKGROUND AND OBJECTIVE: Data on real-world healthcare costs for ixekizumab (IXE) and secukinumab (SEC) in biologic-experienced patients with psoriasis are limited. This study compared real-world costs and healthcare resource utilization between IXE and SEC in biologic-experienced patients with pso...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Shi, Nianwen, Somani, Najwa, Burge, Russel, Zhu, Baojin, Ridenour, Terri, Kern, Scott, Lew, Carolyn, Zimmerman, Nicole, Murage, Mwangi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011324/
https://www.ncbi.nlm.nih.gov/pubmed/36840815
http://dx.doi.org/10.1007/s40261-022-01240-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011324/
https://www.ncbi.nlm.nih.gov/pubmed/36840815
http://dx.doi.org/10.1007/s40261-022-01240-9

Ejemplares similares